# OnCo record nct04868877 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04868877/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04868877", "NCT04868877" ;
  schema:name "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina"@en ;
  schema:description "A phase 1/2 trial of MCLA-129, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Merus B.V., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04868877/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04868877> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-04-28" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/colorectal/> ;
  onco:drugs <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/genmab/> .